MUSIC BROKERS: 25 Years of Success and Expansion in the Music Industry
September 05, 2024 04:57 ET
|
Music Brokers
MILAN, Sept. 05, 2024 (GLOBE NEWSWIRE) -- MUSIC BROKERS celebrates its 25th anniversary, marking a significant milestone in the global music industry. Since its founding in Buenos Aires in 1997 by...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024 16:01 ET
|
Athira Pharma, Inc.
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s...
Kronos Bio Announces Participation in Medical and Investor Conferences in September
September 03, 2024 08:55 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024 09:00 ET
|
AC Immune SA
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
Habit Burger Celebrates Menu Variety with New Name: Habit Burger & Grill
August 28, 2024 07:20 ET
|
The Habit Burger Grill
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Habit Burger, known for its award-winning Charburgers, with its iconic Double Char recently being ranked #1 in USA TODAY’s 10Best, today announces a...
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
August 28, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
We Did It Again: Britannica Education Launches New Wave of Innovations for Back to School
August 27, 2024 10:57 ET
|
Encyclopedia Britannica
CHICAGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Britannica Education, a global leader in reliable, award-winning classroom solutions, today announced comprehensive redesigns across its two flagship...
Helmets to Hardhats Celebrates Success as Key Sponsor of the 165th Running of the King’s Plate
August 27, 2024 10:00 ET
|
Helmets to Hardhats Canada
TORONTO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Helmets to Hardhats proudly served as a major sponsor of the 165th running of the King’s Plate, a landmark event that brought together a distinguished...
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
August 27, 2024 08:00 ET
|
Soleno Therapeutics
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc....